Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

70.16
-0.4900-0.69%
Volume:135.88K
Turnover:9.54M
Market Cap:2.40B
PE:-10.85
High:71.41
Open:71.41
Low:69.41
Close:70.65
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:0.56
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.65
PE(LYR):-7.21

Loading ...

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Jul 25

Nektar Grants 36,000 Inducement Stock Options Priced at $64.84 Per Share

Reuters
·
Jul 25

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Jul 23

Nektar Therapeutics : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $153

THOMSON REUTERS
·
Jul 22

Nektar Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 22

Cantor Fitzgerald Initiates Nektar Therapeutics at Buy With $153 Price Target

MT Newswires Live
·
Jul 22

Nektar Therapeutics Announces Press Release on Start of Phase 3 Zenith AD Program for Rezpegaldesleukin in Atopic Dermatitis

Reuters
·
Jul 21

Nektar Therapeutics - Zenith Ad Program to Enroll 1,530 Patients Across Three Phase 3 Studies

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics Announces Start of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-cell Biologic Rezpegaldesleukin in Moderate-to-severe Atopic Dermatitis

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics - Initial Phase 3 Topline Data Expected Mid-2028; Bla Submission Targeted for 2029

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run

Simply Wall St.
·
Jul 20

Nektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock

TIPRANKS
·
Jul 18

Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 06

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells 5,681 Shares for $397,670

Reuters
·
Jul 03

Nektar Grants New Hires Options for 20,500 Shares at $60.98 Each Under Inducement Plan

Reuters
·
Jun 27

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jun 27

Nektar Therapeutics CEO Robin Howard sells USD 1.2 million in common shares

Reuters
·
Jun 19

Nektar Chief R&D Officer Jonathan Zalevsky sells 5,538 shares for $336,412.98

Reuters
·
Jun 18

Nektar grants inducement stock options for 11,900 shares at $69.49 each

Reuters
·
Jun 04

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 04